Drugs in the News

This Exam is for Home Study Credit only. If you attended a live teleconference and would like to receive Live Credit, please go back to the previous page and click on the Take Exam link listed under the Live Credit section. You will be prompted for the password that was revealed on the teleconference before you can take the exam.

Participants who obtained credit for program number 380-000-05-021-L01 are ineligible to receive duplicate credit for this home-study web broadcast.

Drugs in the News: An Overview of New Therapies

Pharmacy
Program/ACPE #: 380-000-05-021-H01
This program furnishes 1.0 hours of credit (0.1 CEU).

Published Date: December 1, 2005 - Expiration Date: December 1, 2008

Speakers:

Thomas A. Gossel, RPh, PhD
Professor of Pharmacology and Toxicology, Emeritus
Ohio Northern University, Ada, OH

The CE Solution is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This program reflects the opinion(s) of the author(s)/speaker(s) and may not reflect those of the sponsor or publisher. While all reasonable attempts have been made to assure the accuracy of the information contained in this program based on current scientific knowledge at the time of publication, the reader is advised to evaluate their individual patient’s condition, compare information discussed or suggested with recommendations from other authorities, and refer to the official prescribing literature for the latest information on new or highly toxic drugs prior to administration or dispensing.

Statements made in this program have not been evaluated by the Food and Drug Administration. Discussion of published or investigational uses of drugs outside of approved labeling is offered for educational purposes only, and the sponsor and publisher of this program do not endorse such off-label use. Nutritional products discussed are not intended for the prevention, diagnosis, treatment, or cure of any disease.

GOAL

This program provides pharmacists with information on the pharmacology and therapeutics of prescription drugs approved and/or recently introduced into therapy. Focus is on FDA-approved indications and relevant data on the drugs, including trends that will impact future drug discovery and approval.

LEARNING OBJECTIVES

At the conclusion of this program, participants should be able to:
1. Identify the indication(s), pharmacologic action(s), and significant pharmacokinetic principles of the drugs;
2. Recognize important therapeutic applications in specified pathologies;
3. Demonstrate an understanding of adverse effects and toxicity, and significant drug-drug and drug-food interactions; and,
4. Select from a list, information to convey to patients or their caregivers when counseling on the drugs and/or conditions for which they are indicated.

QUESTIONS

1. The results of a study published in 2002 showed that each additional $1 patients spend on newer pharmaceuticals saves them which of the following costs in total health care spending?
a. $1.50
b. $3.33
c. $6.17
d. $9.41
e. $12.72

2. The mechanism of antifungal action of micafungin is closest to which of the following antimicrobials?
a. caspofungin
b. fluconazole
c. griseofulvin
d. ketoconazole
e. terbinafine

3. Tipranavir must be taken along with which of the following drugs to achieve therapeutic blood levels?
a. Hivid
b. Norvir
c. Retrovir
d. Sustiva
e. Viread

4. The drug that is classed pharmacologically as an incretin mimetic agent is:
a. entecavir
b. exenatide
c. mecasermin
d. nepafenac
e. ramelteon

5. Unique to insulin detemir, in contrast to other long-acting insulin formulations, is that the new insulin:
a. causes a greater incidence of lipodystrophy
b. does not form a precipitate at the site of injection
c. is injected intramuscularly rather than subcutaneously
d. must not be used in the same day as a short-acting insulin
e. should be stored in the freezer between doses

6. Increlex is used to:
a. block peptide elongation in susceptible bacteria
b. slow prostate hyperplastic growth
c. stimulate structural bone growth
d. treat chronic hepatitis B infection
e. treat inflammation associated with cataract surgery

7. The drug that acts by stimulating melatonin MT1 and MT2 receptor sites is?
a. Mycamine
b. Naglazyme
c. Nevanac
d. Rozerem
e. Symlin

8. A patient receiving a prescription for Nevanac should be told to:
a. apply a small amount to the skin and rub in well
b. inhale the powder using the enclosed nebulizer
c. inject this medicine under the skin
d. take the liquid on an empty stomach
e. use this medicine in the eye

9. Tygacil belongs to a group of antibiotics considered to be third-generation members of what class?
a. carbipenem
b. cephalosporin
c. erythromycin
d. penicillin
e. tetracycline

10. The drug supplied as a prodrug that must be bioconverted to its active form is:
a. Aptivus
b. Baraclude
c. Levemir
d. Mycamine
e. Rozerem

Back To Lessons

Take Exam